Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
124.54B
Market cap124.54B
Price-Earnings ratio
29.13
Price-Earnings ratio29.13
Dividend yield
Dividend yield
Average volume
2.34M
Average volume2.34M
High today
$503.89
High today$503.89
Low today
$482.20
Low today$482.20
Open price
$482.50
Open price$482.50
Volume
8.69M
Volume8.69M
52 Week high
$507.92
52 Week high$507.92
52 Week low
$362.50
52 Week low$362.50

Stock Snapshot

As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $489.42. The company's market cap stands at 124.54B, with a P/E ratio of 29.13.

As of 2026-06-27, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $482.20 and $503.89. The current price stands at $489.42, placing the stock +1.5% above today's low and -2.9% off the high.

The Vertex Pharmaceuticals(VRTX)'s current trading volume is 8.69M, compared to an average daily volume of 2.34M.

During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $507.92 at its peak.

During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $507.92 at its peak.

VRTX News

Nasdaq 8h
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Phar...

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall St 1d
Vertex Pharmaceuticals Following Fresh CASGEVY Data Has Its Valuation Back In Focus

Vertex Pharmaceuticals (VRTX) is back in focus after fresh Phase 3 data for its gene editing therapy CASGEVY in children aged 5 to 11 with severe sickle cell di...

Vertex Pharmaceuticals Following Fresh CASGEVY Data Has Its Valuation Back In Focus
Simply Wall St 3d
Intuitive Surgical Stock And 2 Cash Rich Picks for Higher Interest Rates

With the Federal Reserve talking tougher on inflation and signaling a possible rate hike within months, investors are rethinking how comfortable they feel with...

Intuitive Surgical Stock And 2 Cash Rich Picks for Higher Interest Rates

Analyst ratings

81%

of 36 ratings
Buy
80.6%
Hold
13.9%
Sell
5.6%

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.